Navigation Links
Pharmacyclics Announces Presentations and Published Abstracts on,Xcytrin at The 2007 American Society of Clinical Oncology Annual,Meeting

SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations and a published abstract regarding Xcytrin(R) (motexafin gadolinium) Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial data. The presentations and publications are part of the proceedings at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) that will be held June 1-5, 2007, at McCormick Place in Chicago, IL.

    The presentations and published abstracts are as follows:


    Sunday, June 3, 2007

    Session: Central Nervous System Tumors

    Oral Presentation: Motexafin gadolinium (MGd) combined with whole brain

    radiation therapy prolongs time to neurologic progression in non-small

    cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis

    of two randomized phase III trials. Abstract #2010: 3:00 - 3:15 p.m.


    Location: S100a

    Presenter: William Shapiro, M.D., Barrow Neurological Institute,

    Phoenix,AZ


    Session: Central Nervous System Tumors


    Poster Presentation: Identification of occult brain metastases amenable to

    stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment

    planning MRI: Results of a phase II trial of MGd and whole brain

    radiotherapy (WBRT) with stereotactic radiosurgery (SRS).

    Abstract #2037: 8:00 a.m. - 12:00 p.m.;

    Discussion: 11:00 a.m. - 12:00 p.m.


    Poster Display Location: S102a; Discussion: S100a

    Presenter: Minesh P. Mehta, M.D., University of Wisconsin


    Motexafin Gadolinium Published Abstract

    Abstract #18001

    Title: A phase II trial of motexafin gadolinium (MGd) in advanced

    non-small-cell lung cancer (NSCLC) patients who had failed platinum-based

    chemotherapy: Preliminary results of Stage 1

About Xcytrin

Pharm acyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins. Its multifunctional mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R), has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.

Web site: http://www.pharmacyclics.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Een app ... zodat zij collectief patiënten kunnen behandelen, hun kennis kunnen ... idee achter de nieuwe en revolutionaire MDLinking App, ontwikkeld ... Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... inmiddels beschikbaar is, wordt op dinsdag 24 mei officieel ...
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... , May 23, 2016 Transparency ... " Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, ... ." According to the report, the exocrine pancreatic insufficiency ... 8.3% from 2015 to 2023 to reach US$2.85 Bn ... a condition characterized by the deficiency of the exocrine ...
Breaking Medicine Technology:
(Date:5/25/2016)... FREMONT, CA (PRWEB) , ... May 25, 2016 , ... ... Most Promising Pharma and Life Sciences Tech Solution Providers list of 2016 by CIOReview. ... Most Promising Pharma and Life Sciences Tech Solution Providers 2016 has been concluded with. ...
(Date:5/25/2016)... ... 25, 2016 , ... The World Molecular Imaging Society (WMIS) ... The focus of ADDMI-IG will be geared towards how using molecular imaging can ... ADDMI-IG WMIS will provide a platform for productive discussions about the implementation of ...
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, ... the developing world, is pleased to release their 2015 global impact data. In ... pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe abortions across 21 countries ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure specializes in ... and pharmaceutical, to food and HVAC facilities. Their knowledgeable staff also takes care ... For medical applications, Afrimesure offers a variety of MadgeTech systems available for sterilization ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only boutique hotel ... stones to complement its new wellness suites . The two 1,350 sq. ft. ... plethora of special services and insuite amenities, from a custom soap selection and in-suite ...
Breaking Medicine News(10 mins):